Abstract
Immunotherapy in prostate cancer is limited because of a lack of immune cells within the tumor. Annels et al. used oncolytic viruses to recruit immune cells into the tumor and showed that in combination with checkpoint inhibitors, which take the brake off of the immune system, established tumors were rejected.
Original language | English (US) |
---|---|
Pages (from-to) | 434-446 |
Number of pages | 13 |
Journal | Molecular Therapy - Oncolytics |
Volume | 20 |
DOIs | |
State | Published - Mar 26 2021 |
Keywords
- Immunotherapy resistance
- Oncolytic virus
- Prostate cancer
ASJC Scopus subject areas
- Molecular Medicine
- Oncology
- Cancer Research
- Pharmacology (medical)